AuthorisedTherapeutic confirmatory (Phase III)Interventional

MidregiOnal proatrial natriuretic peptide to guide SEcondary Stroke prevention: The MOSES-study. An international, multicentre, randomised-controlled, two-arm, assessor-blinded trial.

The MOSES study is a large international research project for adults who have recently experienced a type of stroke called an ischaemic stroke. This is when a clot blocks blood flow to the brain. The study aims to find the most effective way to prevent another stroke from happening. Researchers are comparing several commonly used blood-thinning medicines, like Eliquis, Pradaxa, Lixiana, Plavix, and Aspirin. They are also investigating whether using a particular blood test, which measures a substance called midregional proatrial natriuretic peptide, can help doctors decide which medicine is best for each patient. The main goal is to see which treatment successfully reduces the risk of another stroke within one year.

At a glance

Status

Authorised

Phase

Therapeutic confirmatory (Phase III)

Sponsor

Universitaetsspital Basel

Enrolment target

190

Start

17 Jan 2025

Acute ischemic stroke

What is this study about?

Imagine you've had a stroke, and the main concern is making sure it doesn't happen again. That's exactly what the MOSES study is trying to address. It focuses on people who have recently had an ischaemic stroke, which is the most common type, caused by a blood clot blocking an artery in the brain. The good news is that there are medicines, often called 'blood thinners', that can help prevent future clots and strokes.

This study is looking at several of these established blood-thinning medications. Doctors want to understand if one is more effective than others or if combining a specific blood test with these medicines can help tailor the treatment plan. This blood test measures a substance in your body called midregional proatrial natriuretic peptide, which might give doctors clues about your individual risk of another stroke.

The main aim is to see which approach works best at preventing another stroke within one year of your first one. They'll also be carefully looking at other important things, like any serious bleeding, as well as the overall health and well-being of participants. By carefully comparing these different treatment strategies, the researchers hope to improve how doctors prevent recurrent strokes for people like you.

Key takeaways

Targets adults who have recently had an ischaemic stroke.
Compares different blood-thinning medications.
Investigates if a blood test can help choose the best treatment.
Aims to prevent recurrent strokes within one year.
Participation involves regular check-ups and taking study medication.

Who may be eligible?

To take part in the MOSES study, you need to be an adult, 18 years or older, who has recently had a type of stroke called an ischaemic stroke. This means your stroke was caused by a blood clot.

Both men and women can join the study. There will be other specific medical details that doctors will check to make sure the study is a safe and suitable option for you. For example, they'll need to make sure you don't have certain other health conditions or are taking medications that might interfere with the study treatments.

It's important to talk to your doctor or the study team to find out if this study is the right fit for your personal health situation. They will go through all the detailed requirements with you.

Could this study suit you?

Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.

Are you 18 years old or older?
Have you recently had a stroke caused by a blood clot (an ischaemic stroke)?
Are you comfortable taking study medication as prescribed?
Are you able to attend regular follow-up appointments for one year?

Answer every question to see your result.

What does participation involve?

If you decide to join the MOSES study, you'll be assigned to one of the treatment groups, like flipping a coin, so it's a fair test. You won't get to choose which specific medicine you receive. You'll take the study medication as prescribed, which will be one of the blood-thinning medicines being tested. You'll also have regular visits to the clinic for check-ups, blood tests (including the special one for midregional proatrial natriuretic peptide), and to monitor your health and any side effects. The study will follow you for one year after your stroke to see how you're doing and whether you've had another stroke. The doctors and nurses will explain all the appointments and what's involved in detail.

Potential risks and benefits

Taking part in a study like this might offer potential benefits, such as receiving careful and regular medical attention, and you could potentially benefit from one of the study medications being more effective at preventing another stroke. However, there are also potential risks, as with any medication, including side effects like bleeding, which is a known risk with blood-thinning medicines. The study is designed to monitor these risks very closely. You always have the right to withdraw from the study at any time, for any reason, without it affecting your usual medical care.

Locations (2)

Some site locations are approximate. We're improving this — please verify with the trial team before travelling.

—
Unverified
Greece
—
Unverified
Spain

Common questions

What kind of stroke is this study for?

It's for people who have had an ischaemic stroke, which is caused by a blood clot in the brain.

What medicines are being tested?

Several commonly used blood-thinning medicines like Eliquis, Pradaxa, Lixiana, Plavix, and Aspirin are being compared.

Will I get to choose my medicine?

No, treatments are assigned randomly, like drawing lots, to ensure a fair comparison.

How long does the study last?

You'll be followed for one year after your stroke.

What is the main goal of the study?

To find the best way to prevent another stroke in people who have recently had one.